MX2017006372A - Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular. - Google Patents
Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular.Info
- Publication number
- MX2017006372A MX2017006372A MX2017006372A MX2017006372A MX2017006372A MX 2017006372 A MX2017006372 A MX 2017006372A MX 2017006372 A MX2017006372 A MX 2017006372A MX 2017006372 A MX2017006372 A MX 2017006372A MX 2017006372 A MX2017006372 A MX 2017006372A
- Authority
- MX
- Mexico
- Prior art keywords
- fibrosis
- methods
- extracellular matrix
- fibroblast proliferation
- matrix deposition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title abstract 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title abstract 2
- 230000001594 aberrant effect Effects 0.000 title abstract 2
- 230000008021 deposition Effects 0.000 title abstract 2
- 210000002744 extracellular matrix Anatomy 0.000 title abstract 2
- 210000002950 fibroblast Anatomy 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000035755 proliferation Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 4
- 230000004761 fibrosis Effects 0.000 abstract 4
- 210000001519 tissue Anatomy 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000007634 remodeling Methods 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462080784P | 2014-11-17 | 2014-11-17 | |
| PCT/US2015/061118 WO2016081475A1 (en) | 2014-11-17 | 2015-11-17 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| US14/943,752 US10500249B2 (en) | 2014-11-17 | 2015-11-17 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017006372A true MX2017006372A (es) | 2017-08-21 |
Family
ID=55960752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017006372A MX2017006372A (es) | 2014-11-17 | 2015-11-17 | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10500249B2 (enExample) |
| EP (1) | EP3220943A4 (enExample) |
| JP (1) | JP2018501201A (enExample) |
| KR (1) | KR20170083063A (enExample) |
| CN (1) | CN107106650A (enExample) |
| AU (1) | AU2015350151A1 (enExample) |
| BR (1) | BR112017010238A2 (enExample) |
| CA (1) | CA2967621A1 (enExample) |
| MX (1) | MX2017006372A (enExample) |
| RU (1) | RU2017121090A (enExample) |
| SG (1) | SG11201703939XA (enExample) |
| WO (1) | WO2016081475A1 (enExample) |
| ZA (1) | ZA201703305B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202001379WA (en) * | 2017-09-08 | 2020-03-30 | Bristol Myers Squibb Co | Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash) |
| EP3692073A4 (en) * | 2017-10-03 | 2021-05-26 | Cedars-Sinai Medical Center | METHOD OF TARGETING THE IMMUNE CHECK POINT PD1 SIGNAL PATH FOR TREATMENT OF LUNG FIBROSIS |
| CN108795935B (zh) * | 2018-05-23 | 2022-06-21 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 日本血吸虫SjELAV-like 1基因的siRNA及其应用 |
| CN110575540B (zh) * | 2018-06-07 | 2021-11-02 | 中山大学附属第六医院 | Pdgf抑制剂用于制备治疗肠道炎症疾病的药物方面的用途 |
| CN113134116B (zh) * | 2020-01-20 | 2022-09-06 | 山东威高宏瑞医学科技有限公司 | 内镜微创手术用的填充组合物及填充制剂 |
| CN113952821A (zh) * | 2021-07-22 | 2022-01-21 | 上海安居乐环保科技股份有限公司 | 一种罐区装卸区废气综合治理方法及系统 |
| CN113730551B (zh) * | 2021-09-02 | 2022-11-25 | 徐州医科大学 | Mmi-0100短肽化合物在制备胆汁淤积性肝病治疗药物中的应用 |
| CN118388635B (zh) * | 2024-06-24 | 2024-10-11 | 山东美瑞生物技术有限公司 | 一种提高皮肤修复功能的重组人源化胶原蛋白的制备方法 |
| CN118571492B (zh) * | 2024-08-02 | 2024-10-18 | 天津市胸科医院 | 基于组织边界影响的主动脉夹层患者并发症风险预测模型 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| GB2129691B (en) | 1982-10-08 | 1987-08-05 | Glaxo Group Ltd | Devices for administering medicaments to patients |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| FR2585563B1 (fr) | 1985-07-30 | 1993-11-12 | Glaxo Group Ltd | Dispositif pour administrer des medicaments a des patients |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| WO1995015972A1 (en) | 1993-12-09 | 1995-06-15 | Thomas Jefferson University | Compounds and methods for site-directed mutations in eukaryotic cells |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| WO2000059476A1 (en) | 1999-04-05 | 2000-10-12 | Pharmaceutical Discovery Corporation | Methods for fine powder formation |
| AU779986B2 (en) | 1999-06-29 | 2005-02-24 | Mannkind Corporation | Purification and stabilization of peptide and protein pharmaceutical agents |
| JP5078014B2 (ja) | 2004-08-20 | 2012-11-21 | マンカインド コーポレイション | ジケトピペラジン合成の触媒反応 |
| JP4990142B2 (ja) | 2004-08-23 | 2012-08-01 | マンカインド コーポレイション | 薬物送達のためのジケトピペラジン塩、ジケトモルホリン塩、又はジケトジオキサン塩 |
| KR20070057829A (ko) | 2004-08-23 | 2007-06-07 | 맨카인드 코포레이션 | 포스포디에스테라아제 5형의 억제제의 폐 전달 |
| EP1937219B1 (en) | 2005-09-14 | 2015-11-11 | MannKind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| CN104383546B (zh) | 2006-02-22 | 2021-03-02 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
| EP2155228B1 (en) * | 2007-01-10 | 2014-04-02 | Purdue Research Foundation | Polypeptide inhibitors of hsp27 kinase and uses therefor |
| NL1033850C2 (nl) | 2007-05-15 | 2008-11-18 | 3Force B V | Brandersysteem met voorgemengde branders en vlam-overdrachtsmiddelen. |
| DK2185698T3 (en) | 2007-08-07 | 2015-07-27 | Purdue Research Foundation | Kinase Inhibitors and Uses thereof |
| KR20170001756A (ko) * | 2008-10-20 | 2017-01-04 | 모레 매트릭스 인코포레이티드 | 유착 치료 또는 예방용 폴리펩티드 |
| CN105920582B (zh) | 2008-12-10 | 2020-04-14 | 普渡研究基金会 | 基于细胞渗透性肽的激酶抑制剂 |
| EP2575855A4 (en) * | 2010-05-24 | 2014-03-12 | Moerae Matrix Inc | METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE |
| SG10201604560TA (en) * | 2011-04-12 | 2016-07-28 | Moerae Matrix Inc | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| US9452218B2 (en) | 2012-03-09 | 2016-09-27 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
| US9750718B2 (en) * | 2012-12-12 | 2017-09-05 | The Charlotte-Mecklenburg Hospital Authority | Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity |
-
2015
- 2015-11-17 MX MX2017006372A patent/MX2017006372A/es unknown
- 2015-11-17 BR BR112017010238-2A patent/BR112017010238A2/pt not_active Application Discontinuation
- 2015-11-17 JP JP2017526674A patent/JP2018501201A/ja active Pending
- 2015-11-17 SG SG11201703939XA patent/SG11201703939XA/en unknown
- 2015-11-17 KR KR1020177014506A patent/KR20170083063A/ko not_active Withdrawn
- 2015-11-17 AU AU2015350151A patent/AU2015350151A1/en not_active Abandoned
- 2015-11-17 WO PCT/US2015/061118 patent/WO2016081475A1/en not_active Ceased
- 2015-11-17 RU RU2017121090A patent/RU2017121090A/ru not_active Application Discontinuation
- 2015-11-17 CN CN201580062363.0A patent/CN107106650A/zh active Pending
- 2015-11-17 CA CA2967621A patent/CA2967621A1/en not_active Abandoned
- 2015-11-17 EP EP15861651.6A patent/EP3220943A4/en not_active Withdrawn
- 2015-11-17 US US14/943,752 patent/US10500249B2/en not_active Expired - Fee Related
-
2017
- 2017-05-12 ZA ZA2017/03305A patent/ZA201703305B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017010238A2 (pt) | 2018-02-06 |
| KR20170083063A (ko) | 2017-07-17 |
| WO2016081475A1 (en) | 2016-05-26 |
| US10500249B2 (en) | 2019-12-10 |
| CN107106650A (zh) | 2017-08-29 |
| EP3220943A4 (en) | 2018-08-01 |
| RU2017121090A3 (enExample) | 2019-06-10 |
| EP3220943A1 (en) | 2017-09-27 |
| JP2018501201A (ja) | 2018-01-18 |
| AU2015350151A1 (en) | 2017-06-01 |
| CA2967621A1 (en) | 2016-05-26 |
| US20160136234A1 (en) | 2016-05-19 |
| RU2017121090A (ru) | 2018-12-20 |
| SG11201703939XA (en) | 2017-06-29 |
| ZA201703305B (en) | 2020-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017006372A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular. | |
| MX359516B (es) | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2020004969A (es) | Composiciones y procedimientos para tratar cancer. | |
| NZ739503A (en) | A novel approach for treatment of cancer using immunomodulation | |
| IL308807B2 (en) | Combination therapy for treating cancer | |
| MX2012008999A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012008998A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX342291B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2025009723A (es) | Metodos de tratamiento contra adicciones | |
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| WO2019045248A3 (ko) | 주름 개선 활성을 나타내는 펩타이드 및 이의 용도 | |
| PH12022550448A1 (en) | Niclosamide delayed-release composition and antiviral use thereof | |
| EA033298B1 (ru) | Комбинированная лекарственная форма тезофензина и метопролола | |
| MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| MX2017002476A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. | |
| MX2016011852A (es) | Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi). | |
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| EP4295906A3 (en) | Treatment of restenosis using temsirolimus | |
| PH12016501548B1 (en) | Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases | |
| NZ732301A (en) | Peptide compound, preparation method therefor, and application thereof | |
| EA202090802A1 (ru) | Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью | |
| ZA202001568B (en) | Methods and compositions for treating chronic lung diseases | |
| MX387909B (es) | Tratamiento para la migra?a |